Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern

Vaccine
E N ShlyakhovI Novikov

Abstract

Seven groups (2596 subjects) were vaccinated with a human live anthrax vaccine (HLAV) by three different routes (scarification, subcutaneous and aerosol). The vaccinees were tested for anthrax cell-mediated immunity using the "Anthraxin" skin test at 7, 15, 30, 90, 180 and 365 days following vaccination. The kinetic pattern obtained from all groups, shows a significant, five-phased curve: phase I (2-6 days post-vaccination) shows a slow increase in positive Anthraxin skin reactions. Phase II (7-15 days post-vaccination) shows an exponential rise to a maximum at day 15. Phase III (16-30 days post-vaccination) shows a decrease to day 30. Phase IV (31-90 days post-vaccination) leads to a relative restoration of the positive skin reactions. During phase V (91-365 days post-vaccination) there is a continuous decrease in positive Anthraxin skin reactions. The loss of the skin test reaction on day 30 is a characteristic feature of post vaccination anthrax cell-mediated immunity. It may be due to a blockade of macrophages by lethal anthrax toxin released by the multiplying vaccine strain. Epidemiological observations of HLAV protective rates correlate with the phases of the skin reaction kinetics.

References

Oct 25, 1975·The Veterinary Record·P J Dingle
Aug 1, 1991·Vaccine·P C Turnbull
Feb 1, 1988·Infection and Immunity·J W Ezzell, T G Abshire
Mar 1, 1988·European Journal of Epidemiology·B E Ivins, S L Welkos
Jan 1, 1988·Medical Microbiology and Immunology·P C TurnbullJ Melling
Jan 1, 1988·Microbial Pathogenesis·S L Welkos, A M Friedlander
Jan 1, 1983·Infection and Immunity·P MikesellT M Dreier
Sep 1, 1994·Annals of Internal Medicine·W E Farrar
Jun 1, 1994·Vaccine·E N Shlyakhov, E Rubinstein
Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·P C HannaR J Collier
Jan 1, 1993·Infection and Immunity·A M FriedlanderY Singh

❮ Previous
Next ❯

Citations

May 23, 2002·Current Infectious Disease Reports·Erwin Kurt Cullamar, Larry I. Lutwick
Mar 24, 1999·Ryōikibetsu shōkōgun shirīzu·K WatanabeR Shirakawa
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Jul 20, 2002·Annals of Surgery·Charles E BinkleyLisa M Colletti
Jul 3, 1999·Pharmacotherapy·K H IbrahimJ C Rotschafer
Apr 6, 2007·Expert Review of Vaccines·Dongmei Lu, Anthony J Hickey
Nov 20, 2012·Toxins·Stephanie AscoughDaniel M Altmann
Mar 9, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rebecca J IngramDaniel M Altmann
Feb 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ian Justin GlomskiPierre Louis Goossens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.